About the Editors xv
Acknowledgments xvii
Contributors xix
Introduction 1
Michael J. Barratt and Donald E. Frail
References 5
Part I. Drug Repositioning: Business Case, Strategies, and
Operational Consideration 7
1. Drug Repositioning: The Business Case and Current Strategies
to Repurpose Shelved Candidates and Marketed Drugs 9
John Arrowsmith and Richard Harrison
2. Opportunities and Challenges Associated with Developing
Additional Indication for Clinical Development Candidates and
Marketed Drugs 33
Donald E. Frail and Michael J. Barratt
3. Clinical and Operational Considerations in Repositioning
Marketed Drugs and Drug Candidates 53
Damian O’Connell, David J. Sequeira, and Maria L. Miller
4. Regulatory Considerations and Strategies for Drug
Repositioning 65
Ken Phelps
Part II. Application of Technology Platforms to Uncover New
Indications and Repurpose Existing Drugs 89
5. Computational and Bioinformatic Strategies for Drug
Repositioning Drugs 91
Richard Mazzarella and Craig Webb
6. Mining Scientific and Clinical Databases to Identify Novel
Uses for Existing Drugs 137
Christos Andronis, Anuj Sharma, Spyros Deftereos, Vassilis
Virvilis, Ourania Konstanti, Andreas Persidis, and Aris
Persidis
7. Predicting the Polypharmacology of Drugs: Identifying New
Uses through Chemoinformatics, Structural Informatics, and
Molecular Modeling-Based Approaches 163
Li Xie, Sarah L. Kinnings, Lei Xie, and Philip E. Bourne
8. Systematic Phenotypic Screening for Novel Synergistic
Combinations: A New Paradigm for Repositioning Existing Drugs
207
Margaret S. Lee
9. Phenotypic In Vivo Screening to Identify New, Unpredicted
Indications for Existing Drugs and Drug Candidates 253
Michael S. Saporito, Christopher A. Lipinski, and Andrew G.
Reaume
10. Old Drugs Yield New Discoveries: Examples from the Prodrug ,
Chiral Switch, and Site-Selective Deuteration Strategies 291
Adam J. Morgan, Bhaumik A. Pandya, Craig E. Masse, and Scott L.
Harbeson
Part III. Academic and Nonprofit Initiatives and the Role of Alliances in the Drug Repostioning Industry 345
11. Repurposing Drugs for Tropical Disease: Case Studies and
Open-Source Screening Initiatives 347
Curtis R. Chong
12. Drug Repositioning Efforts by Nonprofit Foundations 389
13. Business Development Strategies in the Repositioning
Industry 433
Aris Persidis and Elizabeth T. Stark
14. A Case Study in Drug Repositioning: Sosei 445
Akinori Mochizuki and Makiko Aoyama
Appendix Additional Drug Repositioning Resources and Links
457
Mark A. Mitchell and Michael J. Barratt
Index 469
Michael Barratt is an independent consultant and previously?Senior Director and Technology Platform Leader at Pfizer's Global Indications Discovery Research Unit. He has?over 15?years of experience in preclinical drug discovery research and leadership.
Donald Frail is an independent consultant and previously?Vice President of Pfizer Global Research and Development and Head of Pfizer's Global Indications Discovery Research Unit. He has over 20 years of industrial research and management experience in preclinical drug discovery and early clinical research.
Overall, this book is so complete that it is a must readfor all the players in drug repositioning, not only researches or drug developers, but also business developmentspecialist, investors, venture capital firms, academia andregulators that need a compressive description that will satisfynovice and more experienced professionals. (ChemMedChem, 1 March 2013)
Ask a Question About this Product More... |